LINCOLN, Neb. -- (BUSINESS WIRE) -- Celerion is pleased to announce the expansion of a formal business presence in Singapore. Heading up the new operations in Singapore is Dr. Chew Lan Chong, MBBS, MRCS, MSc as Executive Director, Medical Research. Dr. Chong brings 10 years of direct operational experience leading clinical pharmacology units.
The opening of the Singapore operations and appointment of Dr. Chong follows quickly after the recent announcements of Celerion’s expansion into South Korea. Celerion announced the opening of clinical operations at Seoul National University Hospital (SNUH) Clinical Trial Center, and collaboration with the Korean Drug Development Fund (KDDF).
The expansion to Singapore and South Korea enables Celerion to provide access for clients to perform innovative and informative early clinical research studies in Asian patients and healthy participants. Through Celerion, clients will have access to patient populations suitable for participation in early clinical research in oncology, hepatitis B, cardiovascular (atherosclerosis and hypertension), diabetes, arthritis, osteoporosis, pain, psychiatric conditions, Alzheimer’s disease, Parkinson’s disease, asthma and COPD. In addition, Celerion’s partners will provide expertise in pharmacogenetics and ethnic bridging studies in Asian populations.
Dr. Chong will lead Celerion’s business operations in Singapore, provide medical and scientific expertise and collaborate with partner early clinical research units to conduct complex early clinical pharmacology studies to the highest global standards.
“We are delighted to continue to build a strong footprint in Asia with our new office in Singapore, headed up by Chew Lan,” said Frederick Pritchard Ph.D, Vice President of Global Drug Development at Celerion. “The continued expansion in Asia demonstrates Celerion’s commitment to providing clients innovative solutions to conduct patient studies. Dr. Chong’s academic qualifications and practical experience make her the perfect choice to head up our operations in Singapore conducting the types of innovative and challenging studies involved in translational and experimental medicine.”
Dr. Chong brings to Celerion a wealth of operational experience, having conducted over 130 early clinical studies at organizations including Pfizer and Lilly in Singapore. Dr. Chong completed postgraduate medical training through The Royal College of Surgeons in Edinburgh. She received her medical degree from Singapore National University. In 2011, she complemented her medical training and industry experience by earning a Master’s degree in Experimental Therapeutics from The University of Oxford.
Celerion, a leader in early clinical research, delivers Applied Translational Medicine. Celerion applies our expertise and experience to translating information gained in research discoveries, to knowledge of drug action and effect in humans to support early drug development decisions and the clinical pharmacology labeling of new medicines.
With over 40 years of experience and 750 global clinic beds (including 24 in-hospital), Celerion conducts and analyzes First-in-Human, clinical Proof-of-Concept, Cardiac Safety Services (TQT, robust QT), ADME and NDA-enabling clinical pharmacology studies. Celerion provides expertise on modeling and simulation, study design, medical writing (protocols and reports), clinical data sciences, biostatistics, and PK/PD analysis as well as small and large molecule bioanalytical assays through clinical drug development. Regulatory, drug development and program management complement Celerion’s service offerings. For more information please visit www.celerion.com.